Phase 1 Trial Begins Dosing Patients With Investigational Brain-penetrant HER2 Inhibitor

Phase 1 Trial Begins Dosing Patients With Investigational Brain-penetrant HER2 Inhibitor
Patient dosing has begun in Zion Pharma's Phase 1 clinical trial in the United States to evaluate the safety of its investigational HER2 inhibitor, ZN-A-1041, in people with HER2-positive breast cancer and other solid tumors. "We are excited to have initiated our Phase 1 trial for ZN-A-1041," Zack Cheng, PhD, chairman, CEO, and co-founder of Zion Pharma, said in a press release. HER2 (human epidermal growth factor receptor 2) is a protein that promotes the growth of some cancers, including about 20% of breast cancers. When a cancer's growth is driven by HER2, that cancer is said to be HER2-positive. Medications that inhibit the activity of this protein — which ZN-A-1041 is designed to do — can slow or stop the growth of HER2-positive tumors. While approved targeted therapies can inhibit HER2 for breast cancer, ZN-A-1041 is being developed to fulfil a specific unmet medical need concerning the brain. Tumors that grow in one part of the body can spread to another part of the body in a process called metastastis. Sometimes, tumors will metastasize to the brain, causing a major health concern. Tumors in the brain complicate treatment because a special cellular barrier — referred to as the blood-brain barrier (BBB) — very tightly controls what substances can pass from the blood into the brain. This normally helps keep the brain free of dangerous toxins, but it can also prevent medications from getting into the brain. Zion Pharma is focused on the development of compounds that can bypass the BBB and penetrate the brain. ZN-A-1041 is the company's lead compound. "With dosing of the first patient in our Phase 1 study, Zion becomes a clinical stage company," Cheng said. "A feat we are particularly proud of as we achieved this within 30 months of forming
Subscribe or to access all post and page content.